Exelon News and Research

RSS
Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson's disease. Side effects may include nausea and vomiting. Administration with a transdermal patch has fewer side effects compared to oral. Elimination is through the urine. It has likely relatively few drug-drug interactions.
More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Investigational drug focuses on slowing Alzheimer's disease progression

Investigational drug focuses on slowing Alzheimer's disease progression

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Alzheimer's drug pioneer to be awarded Israel Prize for Medicine

Alzheimer's drug pioneer to be awarded Israel Prize for Medicine

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Research findings may pave way to new treatment for Alzheimer's disease in humans

Research findings may pave way to new treatment for Alzheimer's disease in humans

Noven Pharmaceuticals files ANDA with FDA for approval of generic version of Exelon

Noven Pharmaceuticals files ANDA with FDA for approval of generic version of Exelon

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

Avraham initiates ladostigil Phase 2 trial in MCI

Avraham initiates ladostigil Phase 2 trial in MCI

New drug candidate may halt mental decline of Alzheimer's

New drug candidate may halt mental decline of Alzheimer's

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Novartis files suit against Watson over generic Exelon

Novartis files suit against Watson over generic Exelon

Dementia needs early diagnosis: Report

Dementia needs early diagnosis: Report

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Watson commences shipment of generic Exelon

Watson commences shipment of generic Exelon

Neuroimaging technique could help in devising effective treatments for Alzheimer's disease

Neuroimaging technique could help in devising effective treatments for Alzheimer's disease

GEH to create a supply of molybdenum-99 for use in nuclear medicine diagnostic procedures

GEH to create a supply of molybdenum-99 for use in nuclear medicine diagnostic procedures

GEH, Exelon Generation agree to a landmark deal to deploy GEH’s isotope generation technology

GEH, Exelon Generation agree to a landmark deal to deploy GEH’s isotope generation technology